SUVEN Life Sciences

Communication to investors
Dec 2014

Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.


FINANCIAL QUICK VIEW

	Q3 Dec 14	PE Dec 14
Growth in revenue	9%	8.17%
Growth in PAT	-11.55%	-17.85%
Growth in EBIDTA	-9.22%	-13.88%
Growth in Pre-R&D EBIDTA	-3.17%	-12.88%
Increase in R&D Costs	31.49%	-7.98%
R&D to sales	9.76%	7.89%


MAJOR PROFITABILITY RATIOS

	Q3 Dec 14	PE Dec 14
PAT to Income	25%	22%
EBIDTA to Income	39%	36%
Cash Flow to Income	28%	26%
Pre-R&D EBITDA to Income	48%	44%


INCOME COMPARISON




PROFIT COMPARISON




EBIDTA COMPARISON




R & D – EXPENDITURE



PRE-R&D EBIDTA



PRE-R&D CASHFLOW



Status for the period ended Dec 2014

- Suven has **725** product patents for **26** inventions and **37** process patents for **7** inventions
- Number of active CRAMS projects - **108**
- SUVN 502 completed Phase **1b** clinical trial in USA and is in preparation for entering into Phase **2a** clinical trial.
- SUVN-G3031 for Cognition in Alzheimer's Disease commenced Phase **1** Clinical Trial in USA under US-IND 123179